In 1995, the group was restructured and thus was formed Cadila Healthcare under the aegis of the Zydus group. From a humble turnover Rs. 250 crores in 1995 the group witnessed a significant financial growth and registered a turnover of over Rs. 14,253 crores in FY20. Adhering to its brand promise of being dedicated to life in all its dimensions, Zydus continues to innovate with an unswerving focus to address the unmet healthcare needs. Simultaneously it rededicates itself to its mission of creating healthier, happier communities across the globe
Financial Results:
Zydus Lifesciences Ltd reported Revenues for Q1FY24 of ₹5,140.00 Crores up from ₹4,073.00 Crore year on year, a rise of 26.2%.
Total Expenses for Q1FY24 of ₹3,832.00 Crores up from ₹3,455.00 Crores year on year, a rise of 10.91%.
Consolidated Net Profit of ₹1,134.00 Crores up 96.88% from ₹576.00 Crores in the same quarter of the previous year.
The Earnings per Share is ₹10.74, up 112.25% from ₹5.06 in the same quarter of the previous year.
*It is important to note that the way the results have been accounted for are slightly different than the ones the companies may choose to publish.
*The presented data is automatically generated. It may occasionally generate incorrect information.